Ovation Science and Skinvisible Expand THC-V Partnership for Obesity Treatment with Novel Transdermal Delivery Technology
核心洞察
Ovation Science (搜索) and Skinvisible Pharmaceuticals (搜索) have enhanced their strategic partnership to develop THC-V (搜索)-based obesity treatments using proprietary Invisicare (搜索)® transdermal delivery technology.
The collaboration targets the global obesity therapy market, projected to reach $150 billion by 2035, with THC-V (搜索) showing promise as an appetite suppressant without psychoactive effects.
The transdermal delivery system aims to address gastrointestinal side effects that limit patient compliance in current obesity treatments while improving bioavailability.
Ovation Science (搜索) Inc. and Skinvisible Pharmaceuticals (搜索) have announced an enhanced strategic partnership to develop cannabinoid-based obesity treatments using advanced transdermal delivery technology. The collaboration builds upon their original 2017 licensing agreement and focuses on leveraging Skinvisible's proprietary Invisicare (搜索)® technology for THC-V (搜索) delivery in the metabolic health sector.
Market Opportunity and Strategic Focus
The partnership targets the substantial global obesity therapy market, which industry analysts project could reach $150 billion by 2035 according to Morgan Stanley. Under the enhanced agreement, Ovation Science (搜索) maintains exclusive worldwide rights to manufacture, private label, distribute, market, and promote licensed products utilizing Skinvisible's delivery technology exclusively with cannabinoids.
The collaboration encompasses comprehensive access to confidential information, including proprietary formulations, processes, methodologies, specifications and trade secrets. A key component includes the recently filed PCT patent-pending application entitled "Transdermal Delivery Composition for Delivery of at least one Glucose Controlling Agent, and Method of Delivering at least one Glucose Controlling Agent."
THC-V as a Therapeutic Agent
The expanded partnership specifically incorporates THC-V (搜索) (tetrahydrocannabivarin), a cannabinoid that recent in-house research has demonstrated potential as a therapeutic agent for obesity management. The compound shows promising results as an appetite suppressant while improving metabolic function through enhanced insulin sensitivity and glucose control. Notably, THC-V offers these therapeutic benefits without the psychoactive effects typically associated with THC.
Addressing Treatment Compliance Challenges
Skinvisible's Invisicare (搜索)® technology represents a significant advancement in transdermal delivery systems for glucose-controlling agents. This innovative approach directly addresses one of the most persistent challenges in current obesity treatments: reducing gastrointestinal side effects that often limit patient compliance and treatment effectiveness.
The transdermal delivery method offers several advantages over traditional oral and injected medications, including improved bioavailability, reduced systemic side effects, and enhanced patient comfort and adherence to treatment protocols.
Leadership Perspective
"We are excited to extend our cannabinoid development into the obesity / metabolic space," said Terry Howlett, Ovation's President. "Skinvisible has demonstrated that they can offer excellent science-based transdermal solutions. With these new developments and patent pending exclusivity we anticipate a positive impact to our financial results and creating value for our shareholders."
Technology Platform and Company Background
Ovation Science (搜索) Inc. and its wholly-owned subsidiary Ovation Science USA Inc. operates as a research and development company developing topical and transdermal CBD/THC and other cannabinoid products. The company's products are powered by the in-licensed patented Invisicare (搜索)® skin delivery technology, which enhances the delivery of ingredients to and through the skin and is protected by patents and proprietary formulations.
With over 20 years of pharmaceutical drug delivery experience, Ovation's management and science team have created a pipeline of proprietary medical and wellness topical and transdermal products. The company generates revenues from royalties on licensees' sales, the sale of Invisicare (搜索) technology, and its own product sales through brands including ARLO CBD Beauty and InVibe® MD.
The strategic collaboration leverages Skinvisible's cutting-edge delivery technology expertise and Ovation Science (搜索)'s cannabinoid background to advance the development and distribution of next-generation cannabinoid-based therapeutics for metabolic disorders. The partnership positions both companies to capitalize on increasing demand for innovative, patient-friendly therapeutic solutions in the rapidly growing metabolic health sector.